ALKBH5 and glioblastoma: Our data demonstrate that targeting ALKBH5 increases radiosensitization of GBMSCs and represses their invasion capability and suggest that ALKBH5 is an attractive therapeutic target to overcome radioresistance and invasiveness of GBM cancer cells.